Merck Company Profile

✉ Email this page to a colleague

MERCK has ninety-two approved drugs.

There are twenty-seven US patents protecting MERCK drugs.

There are seven hundred and forty patent family members on MERCK drugs in sixty-three countries and one hundred and eighty-one supplementary protection certificates in nineteen countries.

International Patents:	740
US Patents:	27
Tradenames:	77
Ingredients:	70
NDAs:	92
Patent Litigation for Merck:	See patent lawsuits for Merck
PTAB Cases with Merck as patent owner:	See PTAB cases with Merck as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PEPCID	famotidine	INJECTABLE;INJECTION	019510-001	Nov 4, 1986		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Merck	VIOXX	rofecoxib	TABLET;ORAL	021042-002	May 20, 1999		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes	9,908,845	⤷ Sign Up	Y	Y		⤷ Sign Up
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-002	Nov 8, 2017		RX	Yes	Yes	RE46791	⤷ Sign Up	Y	Y		⤷ Sign Up
Merck	MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	cefoxitin sodium	INJECTABLE;INJECTION	050581-004	Sep 20, 1984		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	6,890,898	⤷ Sign Up
Merck	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003	6,235,735	⤷ Sign Up
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-003	Nov 18, 1993	4,374,829*PED	⤷ Sign Up
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	7,078,381	⤷ Sign Up
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	5,914,128*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Orally Disintegrating Tablets	2.5 mg and 5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-19
➤ Subscribe	Capsule	40 mg, 80 mg and 125 mg	➤ Subscribe	2008-11-03
➤ Subscribe	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg	➤ Subscribe	2012-11-06
➤ Subscribe	Injection	150 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	For Injection	50 mg/vial and 70 mg/vial	➤ Subscribe	2009-06-26
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Capsules	140 mg and 180 mg	➤ Subscribe	2008-03-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	25 mg, 50 mg and 100 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-25
➤ Subscribe	Injection	115 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	for Oral Suspension	125 mg/Kit	➤ Subscribe	2016-11-23
➤ Subscribe	Oral Solution	70 mg/75 mL	➤ Subscribe	2007-09-07

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	C300357	Netherlands	⤷ Sign Up	PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
1622880	2018C/015	Belgium	⤷ Sign Up	PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU/1/17/1245 20180110
1412357	106 4-2007	Slovakia	⤷ Sign Up	PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001 - EU/1/07/383/018 20070321
1620113	CA 2015 00045	Denmark	⤷ Sign Up	PRODUCT NAME: IVERMECTIN, 22, 23-DIHYDROAVERMECTINB1A + 22,23-DIHRODROAVERMECTIN B1B FOR USE IN THE TREATMNET OF RESACEA; NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402
1429780	SPC/GB12/058	United Kingdom	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.